Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Payables (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Payables for 13 consecutive years, with $4.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 13.05% year-over-year to $4.9 million, compared with a TTM value of $4.9 million through Dec 2025, up 13.05%, and an annual FY2025 reading of $4.9 million, up 13.05% over the prior year.
  • Payables was $4.9 million for Q4 2025 at Abvc Biopharma, up from $4.5 million in the prior quarter.
  • Across five years, Payables topped out at $5.2 million in Q2 2025 and bottomed at $16497.0 in Q3 2021.
  • Average Payables over 5 years is $2.7 million, with a median of $1.9 million recorded in 2022.
  • The sharpest move saw Payables plummeted 86.6% in 2021, then surged 11212.66% in 2022.
  • Year by year, Payables stood at $1.6 million in 2021, then increased by 15.47% to $1.9 million in 2022, then soared by 134.86% to $4.4 million in 2023, then decreased by 2.2% to $4.3 million in 2024, then rose by 13.05% to $4.9 million in 2025.
  • Business Quant data shows Payables for ABVC at $4.9 million in Q4 2025, $4.5 million in Q3 2025, and $5.2 million in Q2 2025.